Bicara Therapeutics Inc. (BCAX) vs Olema Pharmaceuticals, Inc. (OLMA)
Bicara Therapeutics Inc. and Olema Pharmaceuticals, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — BCAX vs OLMA, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Bicara Therapeutics Inc. (BCAX) | Olema Pharmaceuticals, Inc. (OLMA) | |
|---|---|---|
| Market cap | $1.4B | $0.8B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-137.95M | $-162.45M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -34.4% | -33.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Performance — BCAX vs OLMA
Total returns from monthly split- and dividend-adjusted closes; 52-week range from the latest quote. Past performance is not a prediction.
| Bicara Therapeutics Inc. (BCAX) | Olema Pharmaceuticals, Inc. (OLMA) | |
|---|---|---|
| 1-year return | 125.2% | 124.4% |
| 3-year return | — | 5.9% |
| 5-year return | — | -65.8% |
| 10-year return | — | — |
| 52-week range | $8.48–$24.25 | $3.89–$36.26 |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full BCAX vs OLMA breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open BCAX's full financials → Open OLMA's full financials →More comparisons
Frequently asked questions
Which is bigger, BCAX or OLMA?
Bicara Therapeutics Inc. is larger by market capitalization — $1.4B versus $0.8B.
Which grows faster, BCAX or OLMA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.